Increased glomerular alpha 1 (IV) collagen expression and deposition in long-term diabetic rats is prevented by chronic glycosaminoglycan treatment - PubMed (original) (raw)
Affiliations
- PMID: 8780166
Increased glomerular alpha 1 (IV) collagen expression and deposition in long-term diabetic rats is prevented by chronic glycosaminoglycan treatment
M Ceol et al. Lab Invest. 1996 Feb.
Abstract
Diabetic nephropathy is associated with thickening of the glomerular basement membrane and, in particular, with mesangial matrix expansion. Previous studies have indicated that administration of chemically modified, low-anticoagulant heparins prevents some of the morphologic and physiologic alterations occurring in experimental diabetic nephropathy. The effect of prolonged heparin treatment on the glomerular expression and deposition of alpha 1 (IV) collagen, which is a major component of the mesangial matrix, has not been reported previously. Four groups of rats were studied for 12 months: two control groups and two groups of streptozotocin-diabetic rats. One group in each branch received modified heparin continuously from the induction of diabetes. After 12 months synthesis and deposition of alpha 1 (IV) collagglomerula and adjacent tubuli were determined by nonradioactive in situ hybridization and immunohistochemistry. Mesangial cells were localized by Thy 1.1 staining. Long-term diabetes caused a significant increase in alpha 1 (IV) collagen deposition in the mesangial matrix and a more than 2-fold enhancement of glomerular cell alpha 1 (IV) collagen transcript levels, mainly in mesangial cells. The alpha 1 (IV) collagen mRNA levels of proximal tubular cells and visceral epithelial cells were similarly increased. Chronic treatment of diabetic rats with modified heparin completely prevented the increased alpha 1 (IV) collagen deposition and expression. The increased glomerular deposition of alpha 1 (IV) collagen observed in long-term streptozotocin diabetic rats appears to depend on an increased alpha 1 (IV) collagen synthesis. Because chronic application of low-anticoagulant heparin completely prevents the increased alpha 1 (IV) collagen synthesis by mesangial cells, this result suggests a new therapeutic option for the prevention of diabetic nephropathy in humans.
Similar articles
- Differential expression of collagen IV isoforms in experimental glomerulosclerosis.
Bergijk EC, Van Alderwegen IE, Baelde HJ, de Heer E, Funabiki K, Miyai H, Killen PD, Kalluri RK, Bruijn JA. Bergijk EC, et al. J Pathol. 1998 Mar;184(3):307-15. doi: 10.1002/(SICI)1096-9896(199803)184:3<307::AID-PATH5>3.0.CO;2-W. J Pathol. 1998. PMID: 9614384 - Augmented expression of glomerular basement membrane specific type IV collagen isoforms (alpha3-alpha5) in experimental membranous nephropathy.
Minto AW, Kalluri R, Togawa M, Bergijk EC, Killen PD, Salant DJ. Minto AW, et al. Proc Assoc Am Physicians. 1998 May-Jun;110(3):207-17. Proc Assoc Am Physicians. 1998. PMID: 9625527 - Treatment with a glycosaminoglycan formulation ameliorates experimental diabetic nephropathy.
Gambaro G, Venturini AP, Noonan DM, Fries W, Re G, Garbisa S, Milanesi C, Pesarini A, Borsatti A, Marchi E, et al. Gambaro G, et al. Kidney Int. 1994 Sep;46(3):797-806. doi: 10.1038/ki.1994.335. Kidney Int. 1994. PMID: 7527876 - Glomerular changes in diabetes mellitus.
Schleicher ED, Olgemöller B. Schleicher ED, et al. Eur J Clin Chem Clin Biochem. 1992 Oct;30(10):635-40. Eur J Clin Chem Clin Biochem. 1992. PMID: 1493155 Review. - [Effects of glycation process on the macromolecular structure of the glomerular basement membranes and on the glomerular functions in aging and diabetes mellitus].
Sternberg M, Urios P, Grigorova-Borsos AM. Sternberg M, et al. C R Seances Soc Biol Fil. 1995;189(6):967-85. C R Seances Soc Biol Fil. 1995. PMID: 8763028 Review. French.
Cited by
- Therapies on the Horizon for Diabetic Kidney Disease.
Khan SS, Quaggin SE. Khan SS, et al. Curr Diab Rep. 2015 Dec;15(12):111. doi: 10.1007/s11892-015-0685-3. Curr Diab Rep. 2015. PMID: 26458382 Free PMC article. Review. - Sulodexide decreases albuminuria and regulates matrix protein accumulation in C57BL/6 mice with streptozotocin-induced type I diabetic nephropathy.
Yung S, Chau MK, Zhang Q, Zhang CZ, Chan TM. Yung S, et al. PLoS One. 2013;8(1):e54501. doi: 10.1371/journal.pone.0054501. Epub 2013 Jan 22. PLoS One. 2013. PMID: 23349910 Free PMC article. - Anti-proteinuric effect of sulodexide in immunoglobulin a nephropathy.
Bang K, Chin HJ, Chae DW, Joo KW, Kim YS, Kim S, Ju KD, Kim H, Ahn C, Oh KH. Bang K, et al. Yonsei Med J. 2011 Jul;52(4):588-94. doi: 10.3349/ymj.2011.52.4.588. Yonsei Med J. 2011. PMID: 21623600 Free PMC article. Clinical Trial. - Protective effect of sulodexide on podocyte injury in adriamycin nephropathy rats.
Chen S, Fang Z, Zhu Z, Deng A, Liu J, Zhang C. Chen S, et al. J Huazhong Univ Sci Technolog Med Sci. 2009 Dec;29(6):715-9. doi: 10.1007/s11596-009-0608-0. Epub 2009 Dec 29. J Huazhong Univ Sci Technolog Med Sci. 2009. PMID: 20037813 - Expression of fibronectin and TGF-beta1 mRNA and protein suggest altered regulation of extracellular matrix in degenerated disc tissue.
Nerlich AG, Bachmeier BE, Boos N. Nerlich AG, et al. Eur Spine J. 2005 Feb;14(1):17-26. doi: 10.1007/s00586-004-0745-x. Epub 2004 Sep 1. Eur Spine J. 2005. PMID: 15340826 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources